Beyond Biotech - the podcast from Labiotech

2:09 Labiotech.eu news4:16 BIO-Europe (biosaxony)13:54 BIO-Europe (EBD Group EU)28:25 National Hemophilia Foundation44:40 JLLThis week, we have three interviews. Our guests are: Pam Putz, managing director of EBD Group EU; André Hofmann, CEO of biosaxony; and Kevin Mills, chief scientific officer at the National Hemophilia Foundation and Teri Willey, managing director of the National Hemophilia Foundation’s Pathway to Cures. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. BIO-Europe set to start in LeipzigBIO-Europe is returning with a three day in-person event, followed by a three-day virtual option.Taking place at the Leipzig Messe in Leipzig, Germany, from October 24 to 26, there is also an option for those who can’t make it to attend virtually from November 2 to 4.BIO-Europe includes exhibitors, face-to-face partnering meetings, presentations, and a start-up spotlight. More than 4,000 attendees are expected in Germany, with more than 2,200 companies from 60 countries represented. More than 27,000 partnering meetings are anticipated over the three days.For more details on attending BIO-Europe, click here. There is still an option to attend and save €200 by booking before October 14.National Hemophilia Foundation launches research fundThe National Hemophilia Foundation (NHF) in the U.S. has announced the launch of Pathway to Cures (P2C), a new venture philanthropy investment fund focused on creating transformational impact across all inheritable blood disorders. Investing alongside and partnering with traditional private capital funds and other industry organizations, P2C hopes to spur the development of inheritable blood disorder therapies, treatments, and technologies, changing the lives of the inheritable blood disorders community. P2C is being launched as an open-ended fund with an initial $3.5 million commitment from the NHF as it begins fundraising and partnership outreach to raise $20 million over the next several years as it invests in companies that demonstrate significant potential for transformational impact for the inheritable blood disorders community.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter

3:00 News5:04 Omnio14:01 Adocia24:28 Tridek-One29:49 Phenomix Sciences47:27 JLLThis week, we have four guests: Olivier Soula, deputy-CEO and director of R&D at Adocia; Ulrika Norin, CEO of Omnio; Mark Bagnall, CEO of Phenomix Sciences; and Laurence de Schoulepnikoff, CEO of Tridek-One.We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored by Labforward.Adocia takes steps with implants to treat type 1 diabetesFrench biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant by achieving glycemic control without insulin injections in immunocompetent diabetic rats during the 132-day study.AdoShell Islets is an immuno-protective synthetic biomaterial containing islets of Langerhans. After implantation in diabetic animals, the islets encapsulated in AdoShell secrete insulin in response to blood glucose levels. The physical barrier formed by the AdoShell biomaterial allows the implanted cells to be invisible to the host’s immune system while allowing the necessary physiological exchanges to occur for the survival and function of the islets.Phenomix Sciences’ precision obesity biobanking registry and outcomes studyPhenomix Sciences, a precision obesity biotechnology company,has launched a biobanking registry and outcomes study. The registry will evaluate variability in obesity treatment response by collecting patients’ DNA, metabolomics, hormones, and behavioral assessments, in relation to treatment outcomes. The data collected will supplement the 20 billion data points in the Phenomix Sciences Obesity Platform. Mayo Clinic is the first to enroll in the registry and is expected to contribute outcomes from 2,000 patients undergoing obesity treatment.  Outcomes data from biobanks across the registry will supplement Phenomix’s database of biological and clinical data matched to the four obesity phenotypes.  Insights from the database are being used to develop the company’s first therapy selection test, the first of its kind in the obesity space.Tridek-One closes €16M funding round Tridek-One SAS, a French biotech startup specialized in the research and development of CD31 agonists to restore immune balance, recently closed a €16 million ($16.1 million) new financing round.The funds will primarily be used to identify development candidates against auto-immunediseases, to conduct IND-enabling studies and to further build the organization. The company previously raised €3 million in a first round in 2019.Omnio receives funding for plasminogen to treat chronic woundsSwedish company Omnio AB has shown plasminogen is a pro-inflammatory regulator of inflammation that can be used to treat chronic wounds with dysfunctional inflammation.The Umeå-based company, a spin off from Umeå University, said the drug could mean a global treatment revolution for wounds that never heal. The most problematic are diabetic ulcers, venous ulcers, and pressure ulcers. Omnio recently received a capital injection of €1.5 million from its shareholders. SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here

02:17 Labiotech.eu news04:59 TikoMed09:20 Pleco Therapeutics25:45 Cullinan Oncology/World Cancer Research Day44:15 JLLThis week’s podcast has three guests. In honor of World Cancer Research Day on September 24, we have an overview of cancer research with Nadim Ahmed, CEO of Cullinan Oncology; a chat with Ivo Timmermans, CEO of Pleco Therapeutics; and talk with Anders Kristensson, CEO of TikoMed.We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored by Single Use Support, the end-to-end process solution provider for fluid management.World Cancer Research Day: Support research to prevent cancer and catch it earlyFor seven consecutive years, the international research community is marking World Cancer Research Day (WCRD) on September 24, a global movement that seeks to raise awareness of the importance of cancer research to increase survival, facilitate access to scientific advances worldwide and reduce the global burden of cancer. This year, experts in the field of oncology and cancer researchers will focus on cancer health disparities, particularly in the areas of prevention and early detection research and care. The motto this year is Support research to prevent cancer and catch it early.Cullinan OncologyTo talk about the current state of cancer research, we spoke with Nadim Ahmed, CEO of Cullinan Oncology.Cullinan Oncology is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. It finds the most promising clinic-ready cancer therapies through its own discovery efforts and engagement with academic and industry partners. Pleco Therapeutics raises €17.3M to develop AML productPleco Therapeutics BV, a specialty biopharma company in the Netherlands developing novel treatments designed to detoxify the cancer micro-environment has raised total funds of $17.2 million in series A financing. The funds will be used to complete development of, and to commercialize, the company’s novel lead Plecoid product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML).Pleco’s technology provides a platform for the development of a pipeline of therapies. In addition to PTX-061 for AML, the current pipeline includes additional candidates in preclinical testing for the treatment of other rare diseases such as SCLC.Research shows TikoMed’s ILB can treat neurodegenerative diseases including ALSPeer-review research published in Frontiers in Pharmacology supports the broad spectrum mechanism of action of Swedish biopharma company TikoMed’s ILB neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis and function by releasing heparin-binding growth factors. SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter

2:56 News5:42 NLS Days - overview17:42 NLS Days - NLSInvest29:35 NLS Days - AstraZeneca42:13 JLLBeyond Biotech Podcast 14: Nordic Life Science Days 2022This week’s podcast is dedicated to Nordic Life Science Days, otherwise known as NLS Days. This year’s version is an in-person event from September 28-29, at the Malmömässan in Malmö, Sweden.In our preview of NLS Days, which features sessions and fireside chats, company presentations, an exhibition, and one-on-one partnering meetings, we have interviews with managing director of NLSDays, Olivier Duchamp-Giudicelli; Chelsea Ranger, senior advisor, SwedenBIO and chair of NLSInvest; and Magnus Björsne, CEO of AstraZeneca’s BioVentureHub.We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. NLS Days back in personAfter pandemic disruption, NLS Days is returning to an in-person event in Malmö. It is the largest Nordic partnering conference of its kind, and welcomes participants from not only the Nordic countries of Sweden, Denmark, Norway, Finland and Iceland, but also from around the world. NLSDays attracts leading decision makers from biotech, pharma and medtech as well as finance, research, policy and regulatory authorities. Startups and early-phase clinical projects can find new investors, established businesses can find commercial partners for expansion, and global pharmaceutical and biotech companies can evaluate new and promising investment opportunities across the region.The event also features NLSInvest, a pitching contest where 40 regional companies will compete over the two-days. While the event traditionally rotates between Stockholm and Malmö, for its 10th anniversary in 2023 it will be held in Copenhagen at the Bella Centre.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter 

2:32 Labiotech.eu news4:45 BioInnovation Institute20:18 IASP37:38 JLLThis week’s guests on the podcast are Bobby Soni, chief business officer at the BioInnovation Institute, and Harriet Edwards, International Association of Science Parks (IASP) media and community manager.We also have our weekly chat with global commercial real estate services company JLL, and this week it is with Travis McCready. IASP to host World Conference on Science ParksThe 39th IASP World Conference on Science Parks and Areas of Innovation is set to take place in Seville, Spain, from September 27 to 30. This year’s theme is Green and digital change powered by innovation: The role of innovation ecosystems. The IASP is active in 77 countries, and has more than 350 members. Its mission is to be the global network for science parks and areas of innovation, and to drive growth, internationalization and effectiveness for members.It coordinates an active network of managers of science/technology/research parks, innovation districts and other areas of innovation, as well as enhancing new business opportunities for members and their companies.More companies enter BioInnovation Institute Venture Lab programNine ventures and two projects have become the latest addition to The BioInnovation Institute’s (BII) Venture Lab acceleration program for early-stage companies. BII is an international commercial non-profit foundation based in Denmark, which incubates and accelerates life science research.The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – all strategically aligned with BII’s focus on developing scientific initiatives for the benefit of human and planetary health. Designed to help build research-based ideas with high-growth commercial potential into viable start-ups, BII’s 12-month Venture Lab program supports business acceleration, scientific and team development, and provides a risk-free convertible loan of €500,000 ($496,700) plus access to labs and offices at BII’s entrepreneurial ecosystem in the center of Copenhagen. In becoming a part of the Venture Lab program, the early-stage companies also get an opportunity to apply for an add-on opportunity of up to €1.3 million ($1.3 million) through BII’s new Venture House program.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter 

2:48 Labiotech.eu news5:22 Gate Neurosciences16:18 3Brain31:13 Oncolyze50:22 JLLThis week’s podcast guests are Mike McCully, CEO of Gate Neurosciences; Steven Evans, CEO and co-founder of Oncolyze; and Philipp Markolin, scientific marketing specialist at 3Brain.We also have our weekly chat with global commercial real estate services company JLL, and this week it’s a chat with  Amber Schiada, head of life sciences research in the Americas for the company.Gate launches to develop CNS treatmentsGate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.Gate, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges in CNS drug development. Since its founding, the company has acquired a portfolio of next-generation compounds from large pharma, along with corresponding data from thousands of patients dosed across numerous clinical trials that will inform and de-risk future development.Oncolyze set for AML clinical trialsAfter successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials.Oncolyze has designed a novel anti-cancer drug (OM-301) that targets a particular cell surface protein. This protein, HDM2, is known to exist at high levels inside cancer cells and is thought to be an important driver of cancer growth and metastasis. More recently, though, it was discovered that HDM2 is also found on the cell surface of many types of cancer cells, but not normal cells. 3D microchip gives insights into human brainA microchip that allows scientists to study the complexity of 3D cellular networks at unrivaled scale and precision has been added to 3Brain AG’s brain-on-chip portfolio.In collaboration with Swiss precision manufacturing experts, CSEM, 3Brain AG made the announcement last month.The cell-electronic interface technology will also allow scientists to gain novel mechanistic insights into the inner workings of the most complex structure in the universe, the human brain.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter 

2:15 Labiotech.eu news5:12 Phase Genomics16:44 IRB Barcelona29:37 Ilya Pharma43:00 Krystal Biotech53:54   JLLOur guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO of Phase Genomics.We also have a new weekly addition, as JLL will be joining us with a look at financial news. This week, we’re joined by Robert Coughlin, JLL managing director and New England Life Science Practice Group lead.Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instabilityCRISPR allows the introduction of a desired DNA sequence into (virtually) any spot of the genome, thus modifying or inactivating a gene. The technique is widely used in biomedical research and some CRISPR-based therapies are in clinical trials for the treatment of human blood disorders, some types of cancer and HIV.Scientists at IRB Barcelona, led by ICREA researcher Fran Supek, have now reported that, depending on the targeted spot of the human genome, CRISPR gene editing can give rise to cell toxicity and genomic instability. Ilya Pharma finalizes global patent coverage for modified lactic acid bacteria to treat wounds Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents.These are: one in India, and continuation patents in China, Australia and the U.S. This means the company’s method for using modified bacteria for treatment of both mucosal and cutaneous wounds in humans and animals has patent protection in all major markets.Ilya is currently developing a portfolio of three first-in-class immunotherapies for skin and mucosal diseases, including ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors.Krystal Biotech gets green light for cystic fibrosis trialU.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application.The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to the respiratory cells in the lungs. By inducing expression of full length, normal CFTR protein in the lung, treatment with KB407 has the potential to restore ion and water flow into and out of lung cells to correct the lung manifestations of the disease in patients regardless of their underlying genetic mutation.Phase Genomics using ProxiMeta for phage-bacteria interactionsPhase Genomics, Inc., a developer of proximity ligation-based genomic solutions, recently received $5.5M in combined non-dilutive funding from the Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases. With the new funding, Phase Genomics will leverage its phage-bacteria interactome repository to power the development of an  AI-driven predictive engine for therapeutic phage discovery.The new financing will allow the company to harness its proximity-guided metagenomics platform, ProxiMeta, to develop the world’s largest atlas of phage-bacteria interactions and use machine learning tools to identify phages that can be used in therapeutic settings such as C. difficile infections, ulcerative colitis, and Crohn’s disease. <

This week our guests on the podcast are Xianghao Zuo, deputy director of R&D at Triastek; Endpoint Health CEO Jason Springs; and Andy Whiting, CEO of Nevrargenics.2:15 News4:28 Nevrargenics22:26 Triastek37:14 Endpoint HealthTriastek and Lilly working together on 3D printing for drugsA new research collaboration between Chinese company Triastek, Inc. and Eli Lilly and Company will leverage 3D printing technology to achieve precise targeting and programmed drug release in the intestine. Triastek has developed 3D printing technology to provide solutions for drug development. According to the agreement, Triastek and Lilly will focus on improving the bioavailability of drugs in the intestine. Triastek will first conduct in-depth studies of the excipient – inert ingredients added to a drug product for specific functional roles -- to ensure drug stability is maintained during development and 3D printing. Then, Triastek will identify the optimum 3D structure design for achieving targeted and programmed drug release.Triastek has already received two investigational drug clearances from the U.S. Food and Drug Administration for its 3D printed drugs, T19 and T20. Endpoint Health receives funding for precision immunology pipelineEndpoint Health, Inc., a therapeutics company dedicated to addressing unmet needs in immune-mediated acute and chronic diseases, recently recveived $52 million in equity and debt financing. Proceeds from the financing round are being used to extend the company’s Precision-First platform and expand its therapeutic pipeline to include programs for chronic immune-mediated diseases. In addition, proceeds will be used to advance Antithrombin III, the company’s first precision therapy, to a phase II clinical trial for the treatment of sepsis. The company expects to submit its Investigational New Drug application and Investigational Device Exemption to the US Food and Drug Administration for its Antithrombin III program later this year.Completion of the Series A financing follows Endpoint Health’s announcement of a global collaboration and licensing agreement with Grifols to develop and commercialize Antithrombin III in sepsis.NevrargenicsNevrargenics Ltd is a UK drug discovery and development company focused on innovative and novel medicines for neurodegenerative disease.Developed through a commercial team, the research aims to bring a series of drug solutions to market and to service disease areas of major unmet need. The focus area of the company is the development of drugs to target neurodegenerative conditions.Two research groups, based at Aberdeen and Durham universities, have been collaborating for several years, and through this collaboration, have designed, synthesized and identified a lead drug candidate with the potential for establishing new treatment approaches. The strategy is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a series of new rationally designed, effective treatments, meeting that most severe of unmet needs: neurodegeneration.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter

This week's guests are ARCH Venture Partners’ managing director Kristina Burow; founder and CEO of Micropep Thomas Laurent; Kylie O’Keefe, SVP, commercial & corporate strategy at PTC Therapeutics, and Juan Carlos Jaramillo, chief medical officer of Valneva.1:40 News3:47 PTC18:32 Micropep33:01 Valneva42:12 ARCHARCH Venture Partners closes $2.97B biotech fundARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. ARCH Venture Partners is one of the largest early-stage technology venture firms in the U.S. It invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.Upstaza gets EC green lightPTC Therapeutics, Inc. says Upstaza (eladocagene exuparvovec) has been given marketing authorization by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency, and the first marketed gene therapy directly infused into the brain. It is approved for patients 18 months and older.Upstaza also reduced symptoms that cause potentially life-threatening and morbid complications.The marketing authorization is applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.  Micropep raises €8.75M to develop alternative crop-protection productsFrench ag-biotech company Micropep, which develops biological micropeptide-based solutions for agriculture, has completed an €8.75 million ($9.3 million) series A1 financing round. Based in Toulouse, Micropep has developed a technological platform that makes it possible to precisely regulate a plant’s gene expression, without altering its DNA, by the exogenous application of micropeptides, a family of proteins naturally produced by plants to respond to stress and regulate their development.The new investment also marks the first step towards the commercialization of Micropep’s products. Micropep is using this funding to accelerate the development phase of its first micropeptide candidates in the U.S. and will build a locally-recruited team to deploy its solutions. Pfizer and Valneva to start phase 3 Lyme disease vaccine studyPfizer Inc. and Valneva SE have initiated a phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.“With increasing global rates of Lyme disease, providing a new option for people to help protect themselves from the disease is more important than ever,” said Annaliesa Anderson, senior vice president and head of vaccine research and development at Pfizer. Juan Carlos Jaramillo, chief medical officer of Valneva, said, “We are extremely pleased to reach this important milestone in the development of VLA15. Lyme disease continues to spread, representing a high unmet medical need that impacts the lives of many in the northern hemisphere. We look forward to further investigating the VLA15 candidate in phase 3, which will take us a step closer to potentially bringing this vaccine to both adults and children who would benefit from it.”SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on App

This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu.News: 02:30Endogena Therapeutics 5:10eureKARE 21:00Deep Science Ventures 33:46Biotech Growth Trust 47:44Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP).RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for most patients. It is a leading cause of inherited blindness, with an estimated 1.5 million people worldwide presently affected.eureKARE, an investment company focused on financing and building next generation biotech companies in the fields of synthetic biology, has launched its first synthetic biology studio in Belgium. eureKARE is developing a pan-European biotech studio network covering several areas where synthetic biology can create solutions and high market value products.The synthetic biology studios will focus on biomedical and other thematic applications in different European innovation hotspots. The strategy is based on identifying, selecting, and nurturing high-quality European science. The venture builder Deep Science Ventures (DSV) has expanded an existing alliance with Cancer Research UK’s innovation-focused arm Cancer Research Horizons, with the mission to establish new oncology startups in the U.K.Just months after Cancer Research UK (CRUK) established its industry-orientated division Cancer Research Horizons, the research charity has doubled down on a collaboration with DSV, a U.K. venture builder operating in a range of sectors including biotech, agriculture and computation. According to the latest agreement, the partners will co-found startups working in up to 10 areas of oncology, such as improving the number of patients that can benefit from immuno-oncology treatments.The Biotech Growth Trust PLC, based in the UK, seeks capital appreciation through investment in the worldwide biotech industry. It invests in a diversified portfolio of shares and related securities in companies on a worldwide basis.Its portfolio is operated by U.S.-headquartered OrbiMed Capital LLC. Following the strong results of the previous year, the company’s NAV (net asset value) per share total return dropped by 33.8%, compared to a 55.1% increase in 2021, and the share price total return was down 37.0%. However, ​​overall, since OrbiMed’s appointment in 2005, and to the year end, The Biotech Growth Trust’s NAV has increased by 861.6% or 14.3% per annum.In its annual report, the portfolio manager stated the company remains confident that there are a number of potential catalysts that could lead to a recovery in the biotechnology sector this year and into the future, and their overall investment strategy remains unchanged.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear you